GENETIC BIOMARKERS AND PERSONALIZED THERAPY FOR GASTRIC CANCER

Abstract

To integrate and critically interpret evidence on genetic biomarkers and personalized therapy for gastric cancer, based on eight selected studies. Methods: A bibliographic, qualitative, exploratory study synthesizing literature (2000–2025) according to predefined inclusion and exclusion criteria. Results: The review reaffirms HER2 as an established biomarker for targeted therapy in gastric cancer; identifies CDH1, FGFR2, MET and members of the PI3K/Akt/mTOR pathway as emerging targets with limited clinical validation; and highlights the potential of multi-omics strategies and liquid biopsy for patient stratification and monitoring. Limitations: predominance of preclinical studies, methodological heterogeneity and limited sample sizes in several works, restricting generalizability. Conclusion: Precision medicine holds tangible promise for gastric cancer, yet its routine implementation depends on multicenter clinical validation, methodological standardization and integrated multi-omic approaches.